GSK3B and major depressive disorder: These findings, along with clinical reports identifying increases in the activity of GSK3β in postmortem brain samples from patients with major depression (Karege et al., 2007, 2012), have led to the hypothesis that GSK3β is a critical player in the development of major depression that also plays an important role in antidepressant treatment responses (Duda et al., 2020).